By Fineline Cube 
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic capital injection plan, partnering with Green Pine Capital Partners and other institutional investors to inject RMB 300 million (USD 41 million) into its subsidiary Beijing Sungen Biomedical Technology Co., Ltd. The funds are earmarked to accelerate the research and development of Shunjing Bio’s innovative biologic therapeutics.
Sungen Bio’s Pipeline and Progress
Sungen Bio, a clinical-stage biopharmaceutical company, has a pipeline of 10 monoclonal antibody (mAb) candidates. Its lead asset, SGC001, has advanced to a Phase Ib clinical trial for acute myocardial infarction (AMI). This investment will further support the development of its promising therapeutic candidates.-Fineline Info & Tech